Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Adaptimmune's cell therapy hits key goal in pivotal sarcoma test
Adaptimmune is prepping for another FDA submission after its cell therapy was tied to a 42% response rate in a phase 2 sarcoma trial.
Gabrielle Masson
Nov 13, 2024 2:57pm
Merck KGaA tumor trial hits goal, teeing up Daiichi, Ono rivalry
Nov 12, 2024 4:46am
AbbVie's $9B schizophrenia prospect flunks phase 2 trials
Nov 11, 2024 10:06am
UCB's tau drug flunks Alzheimer's trial days after Roche's exit
Nov 1, 2024 6:01am
GemVax's peptide drug fails phase 2a neurodegenerative trial
Oct 29, 2024 11:28am
Analysts hail Vera's kidney drug as potential 'functional cure'
Oct 28, 2024 9:27am
